Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
Collino. Massimo M; Thiemermann. Christoph C; Cerami. Anthony A; Brines. Michael M
Key Findings
- ARA‑290 selectively activates the innate repair receptor (IRR) while avoiding the erythropoietin receptor that raises hematocrit.
- Despite a ~2‑minute plasma half‑life, the peptide triggers sustained biological effects lasting hours to days in disease models.
- Pre‑clinical and early clinical data show reduced inflammation, improved organ protection, and better tissue repair with a good safety profile.
Practical Outcomes
- For biohackers interested in anti‑inflammatory or tissue‑repair strategies, ARA‑290 suggests a way to get long‑lasting benefits from a short‑acting peptide, but it currently requires injection and medical supervision. It may become a useful adjunct for recovery after intense training, injury, or chronic low‑grade inflammation, provided future trials confirm its safety and efficacy.
Summary
ARA‑290 (also called pHBSP) is a tiny 11‑amino‑acid peptide that mimics a part of the hormone erythropoietin but only talks to the body’s “repair” receptor, not the one that makes more red blood cells. Even though it disappears from the blood in about two minutes, it flips a molecular switch that keeps tissue‑protective and anti‑inflammatory pathways active for a long time. Animal studies and early human trials show it can reduce inflammation, protect organs, and aid healing without the clot‑risk that regular EPO has.
Abstract
Many disease processes activate a cellular stress response that initiates a cascade of inflammation and damage. However, this process also triggers a tissue protection and repair system mediated by locally-produced hyposialated erythropoietin (hsEPO). Although recombinant EPO is used widely for treating anemia, potential use of recombinant EPO for tissue-protection is limited by rises in hematocrit, platelet activation, and selectin expression resulting in a high risk of thrombosis. Importantly, the erythropoietic and tissue-protective effects of EPO are mediated by different receptors. Whereas EPO stimulates red cell progenitors by binding to an EPO receptor (EPOR) homodimer, a heterodimer receptor complex composed of EPOR and β common receptor (βcR) subunits, termed the innate repair receptor (IRR), activates tissue protection and repair. The IRR is typically not expressed by normal tissues, but instead is rapidly induced by injury or inflammation. Based on this understanding, EPO derivatives have been developed which selectively activate the IRR without interacting with the EPOR homodimer. The latest generation of specific ligands of the IRR includes an 11 amino acid peptide modeled from the three dimensional structure of the EPO in the region of helix B called pyroglutamate helix B surface peptide (pHBSP; ARA-290). Despite a short plasma half-life (~2min), pHBSP activates a molecular switch that triggers sustained biological effects that have been observed in a number of experimental animal models of disease and in clinical trials. This review summarizes pharmacokinetic and pharmacodynamic data and discusses the molecular mechanisms underlying the long-lasting effects of this short-lived peptide.
Study Information
pubmed
2015
2015-02-26T00:00:00.000Z
10.1016/j.pharmthera.2015.02.005
82
99